NICE's recommendation for NHS to pay for AstraZeneca's non-small cell lung cancer drug Iressa in EGFR mutation-positive patients marks the second personalized medicine product to be funded in the UK after Herceptin was approved in 2002 for HER2-overexpressing breast cancer patients.
Hal Barron, Genentech's chief medical officer, said that "by using [Dako's] diagnostics to help identify the right patients" who will benefit from treatment, Genentech hopes to make Herceptin "the first targeted option for advanced HER2-positive stomach cancer."
CAP and ASCO issued new guidelines to improve accuracy of immunohistochemistry-based ER and PgR testing in breast cancer. The groups estimate that between 10 percent and 20 percent of IHC test results throughout the world may be inaccurate, yielding false-positive or false-negative results.
In the retrospective meta-analysis presented at the European Breast Cancer Conference this week, around 67 percent of patients with CEP17 tumors treated with anthracyclines experienced recurrence-free survival and overall survival in this group was 63 percent.